At The Future of Health.care, we wanted to know more about the start-ups that were presenting at Eye For Pharma this year, that are the core of digital transformation in the healthcare industry. Drugstars is the perfect example of an innovating start-up that can revolutionize healthcare with its patient centered application. We had the chance to interview its CEO, Claus Moldrup.
Claus Moldrup is a pharmacist with a PhD in sociology. He used to be a full-time professor of medicine at Copenhagen University. This combination placed him at the head of a research group of about 110 people at some point. He is now the CEO of Drugstars.
What is Drugstars?
Drugstars is essentially a reward credit platform for patients. From prescription to disposal, points are given. The points/stars are then converted into real cash donations that are given to patient charities. This system also provides valuable data for innovation purposes. You can find more information about the app here!
What makes Drugstars stand out as a company is it’s absolute dedication to the patient. It ensures that patients stick to their medication and course of treatment. The company also adds extra value to the medicine industry by gathering information from the patient’s journey that can help in the production of better treatments.
Drugstars currently has its focus on covering most disease areas. However, in future, it has plans to narrow down its scope to fewer areas to make the best of its expertise.
Digital transformation and trends in the healthcare industry
Regarding health digital transformation and opportunities available in the current world climate, Drugstars is definitely altering its resource as well as time use. Remote work is being given higher value and its potential is being better explored. With the pandemic taking over the world, the value of digital solutions in healthcare cannot be overstated.
Moldrup expressed his optimism about the positive change in patient taxing and overall health care system interaction that will likely come from this crisis. He was less optimistic however about the likelihood of change in the pharma market operations. As the pharmaceutical industry is still on the conservative as well as materialistic side, innovation after the crisis may not be as much as it ought to be.
On the topic of potential trends for 2021, Moldrup hopes to see more clinically validated rather than solely health economy validated apps. He also believes Drugstars has its funding in the right place. The company intends to be the global voice of patients when it comes to pharmaceuticals. Patients should be able to find a safe space within Drugstars to discuss anything from their experience with different medications to treatment outcomes. And by collecting these varied voices and experiences, push them to be heard during dialogues between the pharmaceutical companies and its consumers.
Moldrup considers the healthcare system to be considerably “unhealthy” at the moment. He deems it this way because of the one-track dialogues that are often held on medicine in the pharma industry. The focus usually rests more on pricing, access and privatization. The patient’s voice is not given adequate or proper attention and that is a grave failure. This is where Drugstars comes in to remedy the error by pushing for patient empowerment and ensuring the pharma-payer duo listen more to the patients.
Data from patients are not being properly used yet, according to Moldrup. Patients should be the center of most conversations. More pharmaceuticals should be patient powered. Research and development should be made more with the patient in mind.
If you are interested in knowing more about what Drugstars offers, go on data.drugstars.com!
Claus Moldrup, CEO of Drugstars